The intersection of COVID-19 and neurological complications has highlighted post-COVID anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, a severe autoimmune disorder mediated by antibodies targeting NMDA receptors. This systematic review and institutional case series aimed to synthesize existing literature and present eight new cases from Tehran, Iran, to clarify the pathophysiology, prevalence, clinical manifestations, diagnostic challenges, and therapeutic strategies of this emerging condition. A total of 23 adult patients were analyzed, including 15 cases from the literature and 8 new institutional cases. The mean age was 35.6 years, with a female predominance (60.9%). SARS-CoV-2 infection was confirmed in 91.3% of patients by RT-PCR. The median latency from COVID-19 diagnosis to encephalitis onset was 10 days, with 91.3% occurring within the first month. Neuropsychiatric manifestations were nearly universal (91.3%), including psychosis/hallucinations (56.5%), behavioral or cognitive disturbances (52.2%), seizures (52.2%), movement disorders (34.8%), and altered consciousness (43.5%). MRI revealed abnormalities in 59.1% (most frequently hippocampal involvement), and EEG abnormalities were present in 76.2%, with diffuse slowing, epileptiform activity, and delta brush patterns. Anti-NMDAR antibodies were detected in CSF or serum in 60.9% of cases, with pleocytosis in 34.8%. First-line immunotherapies included intravenous methylprednisolone (87.0%), intravenous immunoglobulin (56.5%), and plasmapheresis (34.8%), while rituximab was used in 30.4% as second-line therapy. At a median 3-month follow-up, 52.2% achieved full recovery, 39.1% partial recovery, and 8.7% died. This study underscores the temporal association between COVID-19 and anti-NMDAR encephalitis, with a consistent clinical phenotype and treatment response resembling classical cases. Early recognition, timely antibody testing, and initiation of immunotherapy are critical to improving outcomes. Larger, prospective studies are warranted to confirm causality, refine diagnostic algorithms, and optimize management strategies.